Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 21, Issue 8, 2001, Pages 1320-1326

  Cheung, Marian C ^a,b   Zhao, Xue Qiao ^a   Chait, Alan ^a   Albers, John J ^a   Brown, B Greg ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Antioxidant vitamins; Coronary artery disease; HDL particles; Lipoproteins; Low HDL

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; ASCORBIC ACID; BETA CAROTENE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; SELENIUM; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DIET SUPPLEMENTATION; FEMALE; HUMAN; LIPID ANALYSIS; LIPID COMPOSITION; MAJOR CLINICAL STUDY; MALE; PARTICLE SIZE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0035572893     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/hq0801.095151     Document Type: Article

References (54)

1. The Coronary Drug Project: Clofibrate, niacin in coronary heart disease
2. Fifteen-year mortality in Coronary Drug Project patients: Long term benefit with niacin
3. The Lipid Research Clinics Coronary Primary Prevention Trial results, I: Reduction in the incidence of coronary heart disease
4. The lipid research clinics coronary primary prevention trial results, II: The relationship of reduction in incidence of coronary heart disease to cholesterol lowering
5. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki heart study
6. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian survival study (4S)
7. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group
8. The effect of pravastatin on coronary events after Myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators
9. The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: Results of the NHLBI type II coronary intervention study
10. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts
11. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B
12. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens
13. Report on the detection, evaluation, and treatment of high blood cholesterol in adults
14. Summary of the second report of the NCEP Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II)
15. High-density lipoprotein cholesterol and cardiovascular disease: Four prospective American studies
16. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
17. Plasma high-density lipoproteins: Metabolism and relationship to atherogenesis
18. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein
19. Comparative study on the effect of low-dose vitamin E and probucol on the susceptibility of LDL to oxidation and progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits
20. Effect of vitamin E, vitamin C, and β-carotene on LDL oxidation and atherosclerosis
21. Lipid and lipoprotein analysis
22. 2+ precipitation procedure for quantitation of high-density lipoprotein cholesterol
23. Enzymatic methods for the quantification of lipoprotein lipids
24. Characterization of lipoprotein particles isolated by immunoaffinity chromatography: Particles containing A-I and A-II and particles containing A-I but no A-II
25. In vitro transformation of apoA-I-containing lipoprotein subpopulations: Role of lecithin:cholesterol acyltransferase and apoB-containing lipoproteins
26. Altered particle size distribution of apolipoprotein A-I-containing lipoproteins in subjects with coronary artery disease
27. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia
28. Effects of a diet restricted in saturated fatty acids and cholesterol on the composition of apolipoprotein A-I-containing lipoprotein particles in the fasting and fed states
29. Concentrations of apolipoprotein A-I-containing particles in patients with hypoalphalipoproteinemia
30. Effects of lovastatin on apoA- and apoB-containing lipoprotein families in a subpopulation of patients participating in the Monitored Atherosclerosis Regression Study (MARS)
31. Apolipoprotein A-I-containing lipoproteins in coronary artery disease
32. Plasma apolipoprotein A-I, A-II, B, E and C-III-containing particles in men with premature coronary artery disease
33. High density lipoproteins and coronary atherosclerosis: A strong inverse relation with the largest particles is confined to normotriglyceridemic patients
34. Effects of long-term treatment with simvastatin on plasma lipids and lipoproteins in patients with primary hypercholesterolemia
35. Effects of simvastatin on apoB metabolism and LDL subfraction distribution
36. The effect of simvastatin on HDL cholesterol in hyperlipidemic patients: Evidence of a relationship with the changes in serum triglyceride level
37. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: Clues to mechanism of action of niacin
38. Complementary effects of pravastatin and nicotinic acid in the treatment of combined hyperlipidemia in diabetic and non-diabetic patients
39. Evaluation of effects of unmodified niacin on fasting and postprandial plasma lipids in normolipidemic men with hypoalphalipoproteinemia
40. Subpopulations of apo A-I in human high density lipoproteins: Their metabolic properties and response to drug therapy
41. Effect of simvastatin on plasma lipids, apolipoproteins and lipoprotein particles in patients with primary hypercholesterolemia
42. Plasma high density lipoprotein particle size alteration by simvastatln treatment in patients with hypercholesterolemia
43. The effects of nicotinic acid treatment on high density lipoprotein particle size subclass levels in hyperlipidemic subjects
44. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism
45. Effects of nicotinic acid therapy on HDL metabolism in type II and type IV hyperlipidemia
46. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by HepG2 cells: Implication for reverse cholesterol transport
47. Molecular biology of phospholipid transfer protein
48. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway
49. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor a-deficient mice
50. Regulation of human apolipoprotein A-I expression in Caco-2 and HepG2 cells by all-trans and 9-cis retinoic acids
51. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor
52. Serum triglyceride elevation following high-dose vitamin treatment for pityriasis rubra pilaris
53. Effect of long-term β-carotene and vitamin A on serum cholesterol and triglyceride levels among participants in the Carotene and Retinol Efficacy Trial (CARET)
54. 2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia: A Probucol Quantitative Regression Swedish Trial (PQRST) report